As an enzyme inhibitor, Apremilast inhibits phosphodiesterase 4 (PDE4), which in turn decreases the expression of pro-inflammatory cytokines TNF-α and IL-23, shows therapeutic efficacy in psoriasis, psoriatic arthropathies, and Behçet’s syndrome (6). The gene discussed is IL23A; the disease is psoriasis.